Meeting
2023 ASCO Annual Meeting
Patient-derived MicroOrganoSpheres (MOS) and precision clinical decision-making for patients with multiple myeloma.
Authors
Rui Xi
Xilis.Inc, Durham, NC
Rui Xi , Xiaobei Wang , Nicholas Baro , Renuka Raman , Shaun Steele , Elena Helman , Shengli Ding , Yubin Kang , Xiling Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8047)
DOI
10.1200/JCO.2023.41.16_suppl.8047
Abstract #
8047
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
First Author: James R. Berenson
Poster
2023 ASCO Annual Meeting
Busulfan, melphalan, and carfilzomib (BuMelCar) conditioning for autologous stem cell transplant (ASCT) in multiple myeloma: Phase I/II data.
First Author: Joseph Allan Norton
Poster
2023 ASCO Annual Meeting
The role of private insurance characteristics in the out-of-pocket costs of patients with multiple myeloma.
First Author: Hamlet Gasoyan
Poster
2023 ASCO Annual Meeting
Identification of genes encoding targets associated with adverse events in multiple myeloma.
First Author: Xuan Xu